“It was a stroke of luck that the drug that most effectively protected normal cells and tissues against radiation also has anti-cancer properties, thus potentially increasing the therapeutic index of radiation therapy,” says Ulrich Rodeck, M.D., Ph.D., Professor of Dermatology and Cutaneous Biology and Radiation Oncology at Thomas Jefferson University, and senior author on the study.
Together with first author Vitali Alexeev, Ph.D., Assistant Professor, Dermatology and Cutaneous Biology, Dr. Rodeck and colleagues tested five compounds that were shown to have radiation-protective properties in earlier studies. The researchers gave the mice one of the five compounds a day before and for several days after radiation treatment. A compound called RTA 408 emerged from this screen as a robust radiation protector and its effect was comparable to the only drug currently approved by the FDA for that purpose. (The approved drug, called amifostine, however, has a number side effects including severe nausea or vomiting that make it an unappealing choice for clinicians.) Sites that are usually most susceptible to radiation damage including the gut and blood cells in the bone marrow were both protected in mice treated with RTA 408.
Using human prostate cancer cells growing in mice, the researchers also showed that RTA 408 did not confer radiation protection to the cancer cells. In fact, when RTA 408 was given alone, without radiation, it also slowed the growth of human prostate cancer transplants in mice. In combination, it further amplified the tumor growth inhibitory effects of radiation.
“It was really exciting to see,” says Dr. Rodeck, “that combining radiation and RTA-408 more effectively inhibited tumor growth compared to using either one or the other as single treatment modalities.”
Dr. Rodeck and colleagues plan to continue to unravel the molecular underpinnings of these radiation-protective effects in order to understand how exactly this compound works and how its mechanism of action might be improved for clinical applications.
RTS 408 is currently being developed by REATA pharmaceuticals for a number of clinical applications, including a trial currently enrolling patients for a topical form of the drug applied to patients who experience radiation dermatitis.
source : http://www.sciencedaily.com/releases/2014/11/141114085400.htm